It has no apparent influence on the severity of coexistent HCV-related chronic liver disease but could be a risk factor for hepatocellular carcinoma in such patients. SEN virus-D/H DNA was detected in 13.5% of patients with chronic liver disease, 11.1% of patients undergoing hemodialysis, and 7.1% of healthy controls, with no significant differences between patients and the control group. Clinical and biochemical steps did not significantly differ between SEN virus-infected and noninfected patients in the chronic liver disease group or the hemodialysis group. The rate of SEN computer virus contamination was significantly higher in patients with chronic liver disease and hepatocellular carcinoma (33.3%) than in those with chronic liver disease only (8.5%) (P< .05). In conclusion, SEN computer virus does not seem to be a common contamination in Egyptian patients. It has no apparent influence on the severity of coexistent HCV-related chronic liver disease but could be a risk factor for hepatocellular carcinoma in such patients. Further studies are needed IM-12 to determine the etiopathogenic role of SEN computer virus contamination in the development of hepatocellular carcinoma. == Introduction == SEN computer virus is usually a IM-12 putative non-A to E hepatitis computer virus.[1]It was first isolated from your serum of an intravenous drug user infected with HIV.[2]By phylogenetic analysis, 9 different strains (A through I) have been recognized and provisionally classified as members of the Circoviridae family, a group of single-stranded DNA viruses that IM-12 includes the TT computer virus (TTV), TUS01, SANBAN, and YONBAN.[35]SEN computer virus is transmitted by blood, as seen by comparing the sequence homology between donors and recipients. Moreover, transfused patients are at higher risk of acquiring SEN virus than are nontransfused ones.[6] Two SEN virus strains (D and H) were shown to be significantly associated with posttransfusion non-A to E hepatitis.[1,7]SEN virus-D and SEN virus-H were also detected more frequently in patients with chronic liver disease and hepatocellular carcinoma than in healthy adults.[8,9]However, the causal relation of these viruses to hepatic disease has not yet been proven. Hepatitis C virus (HCV) is a major cause of posttransfusion hepatitis and chronic liver disease.[10]More than half of patients with acute HCV infection develop chronic hepatitis that leads to cirrhosis and hepatocellular carcinoma, and at least 20% develop both.[11]Among patients with acute or chronic HCV infection, 22% to 85% were reported to be coinfected with SEN virus.[7,1214]Although coinfection of HCV and SEN virus is common, the contribution of SEN virus infection to the course of HCV infection still requires clarification. Patients undergoing long-term hemodialysis are considered to be at risk for infection by blood-borne viruses because that procedure is often associated with bleeding and blood transfusion.[15]These patients may also show hepatic dysfunction consistent with viral hepatitis, even without documented hepatitis A to E infection.[16] The aim of the present study was to determine the prevalence of SEN virus infection among Egyptian patients with HCV-related chronic liver disease and uremic patients undergoing maintenance hemodialysis. We also sought to demonstrate the clinical effect of SEN virus infection on coexistent hepatitis C in terms of severity and probability of developing hepatocellular carcinoma. == Patients and Methods == == Patients and serum samples == The study group consisted of 119 patients who were consecutively examined and followed up at Theodor Bilharz Research Institute in Giza, Egypt. Seventy-four patients had HCV-related chronic liver disease, and 45 patients had uremia and were undergoing maintenance hemodialysis. The chronic liver disease group Rabbit Polyclonal to GNRHR comprised 49 males and 25 females, with a mean age (standard deviation) of 46 11 years (range, 1372 years). Diagnosis of chronic HCV infection was based on the following criteria: 1) detection of HCV RNA or continuous positivity for antibody to HCV (anti-HCV) in serum for more than 6 months; IM-12 2) absence of detectable hepatitis B surface antigen; and 3) exclusion of other causes of chronic liver disease. Diagnosis of chronic liver disease was based on prolonged elevation of serum alanine aminotransferase (ALT) levels for more than 6 months. Liver cirrhosis was diagnosed by histopathologic examination or characteristic clinical signs of advanced liver disease. Hepatocellular carcinoma was diagnosed by histopathologic examination of liver biopsy samples or imaging studies and by serum alpha-fetoprotein levels greater than 400 ng/mL. Serum samples were collected from all patients at the time of clinical evaluation and were stored at 70C until further testing. Eleven patients were receiving alpha-interferon/ribavirin combination therapy for 24 weeks; their serum samples.